Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

27.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts
 
Via Benzinga
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type A 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
 
Via Benzinga
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
 
Via Benzinga
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
 
Via Benzinga
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
 
Via Benzinga
Ultragenyx to Participate in Investor Conferences in December
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
 
Via Benzinga
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in Investor Conferences in September
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
Via Benzinga
Topics Lawsuit
3 Genomics Stocks That May Transform Personalized Medicine
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American Academy of Neurology (AAN) Meeting 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.